Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 17FED 4NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 46Neoplasms 36Colorectal Neoplasms 36Lung Neoplasms 21Breast Neoplasms 13Colonic Polyps 11Colonic Neoplasms 11Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Ovarian Neoplasms 5Motor Activity 5Liver Neoplasms 5Head and Neck Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Adenoma 5Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Urinary Incontinence 3

Interventions

Selective Serotonin Reuptake Inhibitors 1Methylphenidate 1Immunoglobulins 1Citalopram 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
FED × Interventional × Mental Disorders × Clear all
NCT00129467 2015-04-24

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

VA Office of Research and Development

Phase NA Completed
47 enrolled 13 charts

Caregiver Burden, Mental Disorders, Depression, Neoplasms, Pain

NCT00004437 2015-03-25

Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2

FDA Office of Orphan Products Development

Phase 2 Completed
CNS

Mental Disorders, Neurologic Manifestations, Neuroma, Acoustic, Neurofibromatosis 2, Neurofibromatoses, Genetic Diseases, Inborn, Hearing Loss, Rare Diseases

NCT00004682 2015-03-25

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

FDA Office of Orphan Products Development

Phase NA Terminated
100 enrolled

Mental Disorders, Myasthenia Gravis, Neurologic Manifestations, Rare Diseases

NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed
26 enrolled

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡